Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An International, Non-controlled Phase II Trial to Identify the Molecular Mechanisms of Resistance and Sensitivity to Palbociclib Re-challenge Upon Progression to a Palbociclib Combination in ER-positive Metastatic Breast Cancer Patients

NCT03184090 is registered in ClinicalTrials.gov with MedSIR as lead sponsor.

NCT NCT03184090
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03184090 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An International, Non-controlled Phase II Trial to Identify the Molecular Mechanisms of Resistance and Sensitivity to Palbociclib Re-challenge Upon Progression to a Palbociclib Combination in ER-positive Metastatic Breast Cancer Patients
Lead sponsor
MedSIR
Phase
Phase 2
Overall status
Completed
Start date
June 28, 2017
Completion date
October 27, 2020
Enrollment
33 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic breast cancer